Answers are grounded in this paper and cite their sources.
For a patient with a resected gastrointestinal stromal tumor, we base adjuvant decisions on evidence produced after surgery rather than on findings extrapolated from advanced disease. Genotyping comes first, because it identifies the patients who should not receive imatinib: tumors driven by the PDGFRA D842V mutation, succinate dehydrogenase–deficient tumors, and neurofibromatosis type 1–associated tumors do not respond to imatinib, and these patients are spared an ineffective drug. For imatinib-sensitive tumors judged to be at high risk of recurrence by the modified National Institutes of Health or Armed Forces Institute of Pathology criteria, we offer adjuvant imatinib at 400 mg daily for three years, the schedule tested in randomized adjuvant trials. We do not routinely escalate to 800 mg daily for tumors with a KIT exon 9 mutation in the adjuvant setting. The advantage of the higher dose was shown in advanced disease, and the adjuvant cohorts that have examined this question found no benefit from dose escalation after resection. We therefore treat exon 9 dosing as unresolved and discuss the uncertainty with the patient. When the risk of recurrence is highest, we raise the option of continuing imatinib beyond three years and explain that longer treatment delays relapse but has not been shown to cure the disease or prolong survival. Post-resection circulating tumor DNA testing is under study and is not yet part of routine care. We also consider prognostic factors that current risk schemes leave out, and we weigh genotype, clinicopathological risk, and emerging molecular markers together because none of them settles the decision on its own. Within the high-risk group we individualize treatment and offer a clinical trial whenever one is available.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: